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ABSTRACT
Aims: The Schubert–Bornschein type of complete
congenital stationary night blindness (CSNB) is a
genetically heterogeneous retinal disorder. It is charac-
terised by a non-progressive disease course, often
associated with high myopia and nystagmus. So far,
mutations in two genes, NYX (nyctalopin) and GRM6
(metabotropic glutamate receptor 6) have been asso-
ciated with this form of CSNB. The purpose of this study
was to identify the genetic defect in affected male
patients from Flemish families with complete CSNB.
Methods: Probands with CSNB from three large Flemish
families underwent ophthalmological examination. DNA
was extracted from peripheral blood, and the coding
region of NYX along with parts of the 59UTR and 39UTR
and intronic regions covering the splice sites were PCR
amplified and sequenced.
Results: In the affected individuals of three Flemish
families with the complete form of CSNB a novel NYX
mutation, c.855delG was identified. This deletion is
predicted to lead to a frameshift mutation,
p.Asp286ThrfsX62 causing a premature stop codon.
Conclusion: Previously, both single families with different
mutations in NYX as well as different families with an
identical mutation, suggestive of a founder mutation, have
been described. The c.855delG deletion in NYX seems to
be a common mutation associated with CSNB in the
Flemish population from Belgium. Thus, we suggest
performing diagnostic testing for CSNB in the Flemish
population initially directed towards the identification of
this mutation. Subsequent screening for other mutations
in NYX or GRM6 could be performed as a second step.
The Schubert–Bornschein type of congenital
stationary night blindness (CSNB)1 is charac-
terised by a distinctly shaped dark-adapted
combined rod–cone electroretinogram (ERG) to
a single bright white flash: the amplitude of the a-
wave is normal and larger than that of the b-
wave, leading to its electronegative aspect. Under
psychophysical dark adaptation, rod adaptation is
dramatically reduced or completely absent, and
cone adaptation may show variable threshold
elevations in most patients.2–4 Miyake and cow-
orkers further divided this type of CSNB into two
subtypes, incomplete and complete.5 The incom-
plete form of CSNB is characterised by a reduced
rod b-wave as well as a substantially reduced cone
response, while the complete type of CSNB is
associated with either absent or very low ampli-
tudes of the rod b-wave response and normal cone
amplitudes. Both types can be inherited as an X
linked (XL-CSNB) or autosomal recessive (ar)
trait. Mutations in CACNA1F (Xp11.23) and
CABP4 (11q13.1) lead to the incomplete form,
while mutations in NYX (Xp11.4) and GRM6
(5q35) are associated with the complete form of
CSNB.6–13
To date, the majority of mutations have been
identified in two X linked genes, CACNA1F and
NYX, which are assumed to play a role down-
stream of the phototransduction cascade in trans-
mitting the signal from the photoreceptors to the
adjacent bipolar cells.14
NYX comprises three exons and codes for a
protein, nyctalopin, which belongs to the small
leucine-rich proteoglycan family. Although immu-
nofluorescence and western blot analyses have
shown that the protein is attached to the cell
surface via a GPI anchor,15 16 and plays a role in
transmitting the biochemical signal from the
photoreceptors to the adjacent bipolar cells, the
exact role of this protein still has to be discovered.14
Up to now, 37 different mutations in NYX have
been associated with the complete type of CSNB.14
From this total of 37 mutations, 24 single families
have been associated with a different mutation.
The remaining 13 mutations represent different
recurring mutations, most notably a 24 bp dele-
tion, p.Arg29_Ala36del, identified in seven families
originating from the USA with a common foun-
der.9
The objective of this study was to identify the
disease-causing mutation in three apparently unre-
lated large Flemish families with complete CSNB.
MATERIALS AND METHODS
Patients
Informed consent was obtained from the partici-
pants, in accordance with guidelines established by
the Declaration of Helsinki.
Clinical assessments of patients
All affected members of the three families under-
went an extensive ophthalmological evaluation,
including Snellen visual acuity testing, slit-lamp
biomicroscopy, funduscopy, Goldmann visual
fields, colour vision examination, International
Society for Clinical Electrophysiology of Vision
standard electroretinography and on–off
responses (total flash duration of 200 ms), and
infrared, autofluorescence and red-free imaging.
Blood was taken from all family members by
venesection and genomic DNA extracted accord-
ing to accepted procedures (Puregene, Gentra,
Minneapolis).
Mutation analysis
Four PCR fragments containing the exons 1–3 of
NYX were amplified with primers previously
described,17 using DNA polymerase (HotFirePol,
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Figure 1 Pedigrees of patients showing a c.855delG mutation in the NYX gene, which is predicted to lead to a frameshift mutation,
p.Asp286ThrfsX62. Males are represented by boxes, females by circles. Filled boxes indicate that the patient is affected; dots indicate a carrier status;
‘‘wt’’ means ‘‘wild type’’; arrows indicate patients examined.
Figure 2 (A) Composite fundus image
of the right eye of individual IV6 of family
B: note the tilted optic disc with temporal
peripapillary chorioretinal atrophy and
macular hypoplasia with increased
visibility of the choroidal vasculature. (B)
On–off responses of three affected
individuals as indicated on left (LE, left
eye; RE, right eye); representative normal
control at bottom for purposes of
comparison; note the absence of an on-
response in all patients, with preservation
of the off-response. (C) Composite
infrared image of the fundus of the left
eye of individual III14 of family A: note the
tilted disc, pronounced peripapillary
atrophy and macular hypoplasia. (D)
Autofluorescence image of the fundus of
the right eye of individual III14 of family A:
background autofluorescence is normal.
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Soli Biodyne, Tartu, Estonia), 1.5 mM MgCl2 (exon 1–2,
fragments B and C of exon 3) or 2.5 mM MgCl2 (fragment B
of exon 3) and an annealing temperature of 56uC (exons 1–2) or
58uC (all fragments of exon 3) in the presence of Q-solution
(Qiagen, Hombrechtikon, Switzerland). Purification and
sequencing were performed with the appropriate primers as
described earlier.12 The DNA of 43 Flemish females and 51
Flemish unaffected males served as controls for this study.
Figure 3 International Society for Clinical Electrophysiology of Vision standard full-field flash electroretinography (ERG) of four representative
congenital stationary night blindness patients (LE, left eye; RE, right eye) as indicated on the left, and representative normal control at the bottom: note
the typical Schubert–Bornschein complete type abnormalities with: absent or residual rod-specific responses, electronegative mixed rod–cone
responses; absent scotopic oscillatory potentials, cone-specific responses to transient flash with normal amplitudes but broadened a-wave due to loss
of photopic oscillatory potentials (slight delay in individual III14 of family A), and (near-) normal cone responses to 30 Hz flickering stimulus.
Table 1 Haplotype analysis of the patients with the c.855delG mutation in NYX
Marker Position cM
Alleles of patients
AIII14 AV1 AIV4 BIV6 CV1 CV3 CV4
DXS993 63.90 307 307 307 307 307 307 307
NYX [c.855delG] [c.855delG] [c.855delG] [c.855delG] [c.855delG] [c.855delG] [c.855delG]
DXS6810 66.88 222 222 222 222 222 222 222
DXS8035 70.00 138 138 138 138 138 138 138
Laboratory science
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Genotyping
Four polymorphic microsatellite markers were used for geno-
typing the affected individuals of families A, B and C (fig 1).
Products of PCR assays with fluorescently labelled primers were
analysed by automated capillary genotyping on an ABI 3730
DNA Analyser (Applied Biosystems, Foster City, California) and
scored using the GeneMapper analysis software (Applied
Biosystems).
RESULTS AND DISCUSSION
All seven affected family members of the three Flemish families
have been diagnosed as having complete CSNB (fig 1). The
diagnosis was based on a combination of congenital night
blindness without photophobia, subnormal best-corrected
visual acuity with nystagmus but (near-) normal visual fields,
a documented personal or family history of stationary disease,
fundus changes limited to myopia with macular hypoplasia,
absence of hyperautofluorescence on autofluorescence imaging
(fig 2) and Schubert–Bornschein complete type ERG abnorm-
alities (figs 2, 3 and supplementary table 1). All patients are
males and have a family history compatible with X linked
inheritance. The three families are apparently unrelated (fig 1).
They had all been diagnosed in their first few years of life, after
failing to fix and follow at the age of 3 months, in the presence
of nystagmus. Normal fundus autofluorescence imaging, which
was performed in six patients, further supported the stationary
nature of the disease.
The DNAs from seven male patients from the three different
families were screened for mutations in the NYX gene. In all of
them, a c.855delG was identified (fig 4).
Additionally, also the carrier status of four unaffected females
of these families has been investigated (A-IV3, A-IV10, B-IV7, C-
IV7) (fig 1). Only B-IV7 did not carry the mutation. These
studies clearly showed that the mutation c.855delG co-
segregates within these families. None of the 137 control alleles
from the same population revealed this mutation. The deletion
is predicted to lead to a shift in the open reading frame,
p.Asp286ThrfsX62, and causes a premature stop codon.
Microsatellite screening of markers near the NYX locus revealed
that all affected individuals of the three Flemish families share
the same haplotype in the 6.1 cM region limited by the markers
DXS993 and DXS8035 (see table 1). The haplotypes of a close
located marker DXS1068 at position 60.25 cM are distinct in the
different families but also within the same family, indicating
that recombination occurred (data not shown).
These studies suggest that a common founder mutation of
NYX is associated with the complete form of CSNB in the
Flemish population of Belgium. Consequently, molecular test-
ing in Flemish patients with a suspected diagnosis of complete
CSNB should be directed first towards identification of this
common mutation by sequencing only the respective part of
exon 3 of NYX. After exclusion of this common mutation,
screening for other mutations in either NYX or GRM6 can be
performed as a second step.
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